Nursing facility
Baker County Medical Services INC
Baker County Medical Services INC was paid $2.44M by Medicaid between Jan 2018 and Nov 2024, across 59 billing codes. Its largest line is 99283, emergency room visit (moderate) — 33% of everything it billed.
33Billing provider infoBAKER COUNTY MEDICAL SERVICES INC
MACCLENNY, FL 32063
MACCLENNY, FL 32063
33aNPI1104926401assigned 09/25/2006
33bProvider typeSkilled Nursing Facility
28Total paid$2.44M
24GClaims86,201
24DCodes billed59
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Skilled Nursing Facility providers in Florida
Rank by total paid#48 of 685
Median peer was paid$160K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,521 | $110K | |
| 2019 | 16,056 | $338K | |
| 2020 | 15,366 | $310K | |
| 2021 | 16,670 | $464K | |
| 2022 | 18,958 | $649K | |
| 2023 | 10,736 | $403K | |
| 2024incomplete | 1,894 | $162K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 33% | 8,312 | 7,221 | $811K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 4,110 | 3,547 | $398K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 1,955 | 1,526 | $236K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.2% | 779 | 634 | $150K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.2% | 911 | 712 | $126K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.4% | 714 | 658 | $107K |
| 36415 | Collection of venous blood by venipuncture | 3.1% | 9,042 | 5,653 | $77K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 1,197 | 807 | $74K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 579 | 529 | $64K |
| 80053 | Comprehensive metabolic panel | 1.7% | 6,523 | 4,737 | $41K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 879 | 639 | $41K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 7,069 | 5,036 | $25K |
47 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 212 | $21K |
| 81025 | <1% | 1,197 | $19K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,768 | $19K |
| 84484 | <1% | 2,332 | $17K | |
| 83880 | <1% | 2,249 | $16K | |
| 94761 | <1% | 2,717 | $16K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,353 | $16K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,415 | $15K |
| 82550 | <1% | 2,285 | $15K | |
| 83615 | <1% | 2,226 | $15K | |
| 81001 | <1% | 3,791 | $14K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,653 | $13K |
| 85610 | <1% | 2,057 | $11K | |
| 85730 | <1% | 1,484 | $11K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,053 | $10K |
| 87275 | <1% | 2,418 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,088 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 224 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,121 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 692 | $5K |
| 83690 | <1% | 841 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 94 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,659 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,248 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 945 | $2K |
| 80061 | Lipid panel | <1% | 795 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 33 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 491 | $747.89 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 464 | $721.75 |
| 87040 | <1% | 26 | $531.84 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 25 | $484.98 |
| 82330 | <1% | 36 | $460.17 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18 | $366.29 |
| 82803 | <1% | 37 | $357.76 | |
| 83605 | <1% | 45 | $357.76 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 349 | $319.99 |
| 86328 | <1% | 28 | $313.55 | |
| 82553 | <1% | 17 | $201.14 | |
| 84439 | <1% | 159 | $165.40 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 91 | $115.33 |
| 87807 | <1% | 187 | $28.65 | |
| 87276 | <1% | 44 | $8.84 | |
| 82607 | <1% | 31 | $7.16 | |
| 81002 | <1% | 42 | $3.41 | |
| 83735 | 0% | 15 | $0.00 | |
| 96368 | 0% | 23 | $0.00 | |
| 82947 | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVARNADOE, TIFFANY (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Baker County Medical Services, INC | Macclenny, FL | $366K |
| Baker Community Health Center INC | Macclenny, FL | $32K |
| Baker County Medical Services INC | Macclenny, FL | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.